ofloxacin has been researched along with Hemangioma in 1 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Hemangioma: A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Perioperative use of ofloxacin for prophylaxis was investigated in 20 patients with focal hepatic formations (hemangioma, adenocarcinoma, echinococcosis)." | 5.10 | [Perioperative management of focal liver diseases by ofloxacin]. ( Elagina, LV; Ikramov, RZ; Izotova, GN; Khlebnikov, EP; Kybyshkin, VA; Pavlova, MV; Vishnevskiĭ, VA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khlebnikov, EP | 1 |
| Elagina, LV | 1 |
| Vishnevskiĭ, VA | 1 |
| Kybyshkin, VA | 1 |
| Izotova, GN | 1 |
| Pavlova, MV | 1 |
| Ikramov, RZ | 1 |
1 trial available for ofloxacin and Hemangioma
| Article | Year |
|---|---|
[Perioperative management of focal liver diseases by ofloxacin].
Topics: Adenocarcinoma; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Antibody Formation; Echi | 2002 |